Eyetech Pharmaceuticals, Inc. Announces Price for Macugen(R) (pegaptanib sodium injection)

Eyetech Pharmaceuticals, Inc. Announces Price for Macugen(R)
(pegaptanib sodium injection)
Will Host Live Discussion of Launch Plan 


NEW YORK, Dec. 22  /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc.
(NASDAQ:EYET) today announced that the list price for Macugen(R) (pegaptanib
sodium injection) will be $995 per injection. Macugen was approved by the FDA
on December 17, 2004 for use in the treatment of neovascular (wet) age-related
macular degeneration, an eye disease associated with aging that destroys
central vision.

Eyetech management will host a conference call regarding the pricing strategy
and the launch plan for Macugen on Wednesday January 5, 2005 at 8:30AM EST,
before the US markets open.  Live audio of the call will be available to
investors, members of the news media and the general public by dialing
888-275-0218 (in the United States) or 706-679-7756 (internationally). A
playback of this event will be available through January 19, 2005 by dialing
800-642-1687 (within the United States) or 706-645-9291 (internationally). The
passcode for this replay will be 3062807.  In addition, this discussion will be
broadcasted simultaneously over the Internet and the webcast can be accessed by
logging on to the Investor Relations section of our corporate website at
http://www.eyetech.com/.  An archived version of the webcast will be available
at the same location through January 19, 2005.

About Eyetech Pharmaceuticals, Inc.

Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes
in the development and commercialization of novel therapeutics to treat
diseases of the eye. Eyetech's initial focus is on diseases affecting the back
of the eye. Eyetech is commercializing and further developing Macugen(R)
(pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular
AMD. Macugen is also being studied for the treatment of diabetic macular edema
and retinal vein occlusion.

Safe Harbor Statement

This press release contains a forward-looking statement that involves
substantial risks and uncertainties. You should not place undue reliance on our
forward-looking statements. Various important factors could cause actual
results or events to differ materially from the forward-looking statement that
we make, including risks related to: achieving acceptance of Macugen by the
medical community, by patients receiving therapy and by third party payors;
supplying sufficient quantities of Macugen to meet anticipated market demand;
the impact of competitive products; our dependence on third parties to
manufacture Macugen; new information arising out of clinical trial results; and
the success of Macugen's launch generally. These and other risks in investing
in Eyetech are described in greater detail in the "Risk Factors" section of our
most recent quarterly report on Form 10-Q filed with the SEC. We do not assume
any obligation to update any forward-looking statements. 

DATASOURCE: Eyetech Pharmaceuticals, Inc.



CONTACT: Karin Hehenberger, M.D., Ph.D, Senior Director of Scientific and

External Affairs of Eyetech Pharmaceuticals, Inc., [phone],

Fax: [phone],  



Web site:  http://www.eyetech.com/ 

Copyright